RSV Vaccine Efficacy in Pregnancy

Author(s):

Carrie Koenigsfeld, PharmD, FAPhA

Carrie Koenigsfeld, PharmD, FAPhA, highlights the main findings from the MATISSE trial, which evaluated the safety and efficacy of a non-adjuvanted RSV vaccine administered to pregnant women, presenting data that suggests the vaccine's effectiveness in preventing severe RSV in infants and discussing the observed adverse events in both mothers and infants.

EP: 1.Adjuvant RSV Vaccine in Older Adults

EP: 2.Non-adjuvant RSV Vaccine in Older Adults

Now Viewing

EP: 3.RSV Vaccine Efficacy in Pregnancy

EP: 4.Who Not to Vaccinate Against RSV

EP: 5.RSV Vaccine Administration Timing and Errors

EP: 6.Role of the Pharmacist in Vaccinating Against RSV

EP: 7.What is RSV?

EP: 8.Lasting Impacts of RSV

EP: 9.Limiting Transmission of RSV

EP: 10.Preparation of RSV Vaccines

EP: 11.Role of Pharmacists in Improving Vaccine Uptake

EP: 12.Pharmacists Enhancing RSV Care

What were the key results from the MATISSE trialregarding the safety and efficacy of the non-adjuvanted vaccine in pregnant women?
1. Efficacy in preventing severe RSV in infants
2. Adverse effects in maternal and infant subjects
3. Trial limitations: no high-risk pregnancies